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Abstract. Human epidermal growth factor receptor-2 (HER2) 
is overexpressed in 15-20% of breast cancer patients and is asso-
ciated with an aggressive tumor and a poor prognosis. Currently, 
patients are selected for adjuvant HER2-targeted therapy based 
on HER2 status by immunohistochemistry (IHC) and fluores-
cence in situ hybridization (FISH). In this study, we assessed 
the clinical significance of tissue HER2 status determined 
by a quantitative immunoassay using ADVIA Centaur. We 
investigated the hypothesis that the clinical outcome is worse 
in a group of patients defined as tissue HER2-positive only by 
Centaur, but not treated with adjuvant HER2-targeted therapy, 
compared to patients defined as HER2-positive by IHC/FISH 
and therefore treated with adjuvant HER2-targeted therapy. 
Tumor tissue was obtained at primary surgery from 415 breast 
cancer patients between 2004 and 2010. HER2 status was deter-
mined by quantitative immunoassay of fresh-frozen tissue and 
by IHC/FISH of corresponding paraffin-embedded tissue. We 
compared the clinical outcome in four groups of patients defined 
by tissue HER2 status and adjuvant HER2-targeted therapy. 
The final analysis included 379 patients after a median follow-
up of 3.9 years for invasive disease-free survival (IDFS) and 4.2 
years for overall survival (OS). The quantitative Centaur assay 
defined a greater number of patients (100 patients, 26.4%) as 
HER2-positive than IHC/FISH (63 patients, 16.6%) (P<0.0001). 
No significant difference in IDFS (P=0.159) and OS (P=0.150) 
was observed among the four groups of patients. However, in 
the IHC/FISH-positive group without adjuvant HER2-targeted 
therapy (group 2), a significantly greater number of events was 
found compared to the Centaur-positive group without adjuvant 
HER2-targeted therapy (group 3) for both IDFS (P=0.025) and 
OS (P=0.020). Quantitative HER2 determination by Centaur did 
not define a new group of patients eligible for HER2-targeted 
therapy. Currently, tissue HER2 status defined by IHC/FISH 
analysis remains the gold standard.
Introduction
Breast cancer is the leading cancer among women in the indus-
trialized world and 15-20% of breast cancer tumors feature an 
overexpression and/or amplification of human epidermal growth 
factor receptor-2 (HER2). HER2, also termed HER2/neu, ErbB2 
or p185HER2, is one of four tyrosine kinase receptors of the 
HER family which includes HER1 (EGFR), HER2, HER3 
and HER4. The HER2 gene is located on chromosome 17 and 
encodes HER2, which is a 185-kDa glycoprotein composed of an 
intracellular tyrosine kinase domain, a transmembrane domain, 
and an extracellular domain with a yet unknown ligand (1). 
Activation of the HER2 pathway is presumably driven by the 
binding of heregulins to HER3 and HER4 or EGF to HER1 and 
the subsequent hetero-dimerization with HER2, which leads to 
the activation of the downstream pathway (2).
Overexpression of the HER2 protein and/or amplifica-
tion of the HER2 gene leads to tumor cell proliferation and is 
associated with an aggressive tumor and a poor prognosis (3,4). 
Furthermore, HER2 overexpression/amplification predicts the 
effect of HER2-targeted therapy (e.g., trastuzumab and lapatinib) 
in combination with chemotherapy in both the metastatic and 
adjuvant setting, and several studies have demonstrated that the 
addition of trastuzumab reduces the risk of recurrence in HER2-
positive breast cancer patients by approximately 50% (5-7).
Several studies have reported the discordance of HER2 
status between primary and recurrent disease years after the 
primary treatment in 3-14% of the cases (8-10). This has led to 
the hypothesis that an additional group of patients may benefit 
from HER2-targeted therapy in the adjuvant setting. However, 
it remains unclear whether the observed discordance of HER2 
status is due to heterogeneity of the primary tumor, acquired 
HER2 expression during the course of the disease, or limited 
sensitivity of the assay leading to misclassification of a modest, 
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but clinically relevant HER2 overexpression. Currently, 
patients are selected for adjuvant HER2-targeted therapy 
based on immunohistochemistry (IHC) and fluorescence- or 
chromogenic in situ hybridization (FISH, CISH) (11). In addi-
tion to these semi-quantitative tests, quantitative real-time 
PCR and microarray-based RNA expression analysis of HER2 
have emerged over the past decade, delivering quantitative 
estimates of HER2 DNA and RNA expression (12-14).
In this study, tissue HER2 status was determined by a 
quantitative immunoassay using ADVIA Centaur. This assay 
is able to analyze a larger tumor amount, whereby the influence 
of tumor heterogeneity is reduced compared to IHC/FISH. By 
using this method, an additional 9% of patients were classified 
as HER2-positive compared to the conventional IHC/FISH 
methods as reported in a previous study by Olsen et al (15). 
The clinical relevance of this information however, is unknown 
and therefore, the aim of the present study was to perform a 
clinical evaluation of the quantitative Centaur assay. We wished 
to examine the hypothesis that the clinical outcome is poorer in 
a group of patients defined as tissue HER2-positive by Centaur 
only, but not treated with adjuvant HER2-targeted therapy, 
compared to patients defined as HER2-positive by IHC/FISH 
and therefore treated with adjuvant HER2-targeted therapy.
Patients and methods
Study population and patient samples. This prospective cohort 
study was performed in a single center cancer hospital. Women 
eligible for primary surgery for breast cancer stages I-IIIA 
were included after written informed consent. The study 
was approved by the Regional Scientific Ethics Committee 
for Southern Denmark (project identification number S-VF-
20040101). Tumor tissue samples and auto logous reference 
tissue samples were obtained from 415 breast cancer patients 
between 2004 and 2010. Surgery was performed in accor-
dance with the guidelines from the Danish Breast Cancer 
Cooperative Group (DBCG).
The tissue samples were obtained within 1 h after surgery. 
One part of the sample was fixed in formalin and paraffin-
embedded for IHC/FISH analysis. The other part of the sample 
was snap-frozen in liquid nitrogen and stored in a local biobank 
at -80˚C for later Centaur analysis. A dedicated pathologist 
verified the presence of tumor tissue in the tumor sample and 
the lack of tumor tissue in the autologous reference tissue. 
Reference tissue was taken at least 1 cm away from tumor 
tissue whenever possible.
A total of 36 patients were excluded from the final analysis 
due to advanced disease, benign pathology, neoadjuvant 
chemotherapy, or missing tumor tissue (flow diagram, Fig. 1). 
The mean age of the remaining 379 patients was 60 years 
(34-91 years). A total of 272 patients (71.8%) were treated 
with breast-conserving surgery, while 107 (28.2%) had a 
mastectomy. Only 17 patients (4.5%) had bilateral synchronous 
breast cancer. The majority of patients (330 patients, 87.1%) 
had invasive ductal carcinoma, 25 patients (6.6%) had invasive 
lobular carcinoma, and 24 patients (6.3%) had other types of 
breast cancer.
End points. End points were defined according to the standard 
definitions by Hudis et al (16) Invasive disease-free survival 
(IDFS) was defined as the time from primary surgery to 
one of the following events: ipsilateral invasive breast tumor 
recurrence, regional invasive breast cancer recurrence, distant 
recurrence, death by any cause, contralateral invasive breast 
cancer, or second primary non-breast invasive cancer. This 
definition excludes all types of carcinoma in situ [ductal carci-
noma in situ (DCIS), lobular carcinoma in situ (LCIS) and all 
in situ cancers of non-breast sites] and squamous or basal cell 
skin cancers. Overall survival (OS) was defined as the time 
from primary surgery to death by any cause (includes death 
from breast cancer, non-breast cancer or unknown causes).
Clinical and histological data. Pathological data were obtained 
from the DBCG database and verified in the local database at 
the Department of Pathology, Vejle Hospital, Vejle, Denmark. 
Clinical IDFS data were obtained from the local electronic 
health records and the nationwide online electronic health 
records holding data from all Danish hospitals. OS data were 
obtained from the nationwide Danish Civil Registration System, 
which contains basic personal data on all residents in Denmark.
Tissue HER2 determination. Homogenization of the tissue 
samples and determination of the tissue HER2 status and 
estrogen receptor (ER) status have been described in detail 
in a previous study of ours [Olsen et al (17)]. The quantitative 
detection of HER2 tissue concentration was determined using 
fresh-frozen tumor tissue and autologous reference tissue by 
means of commercially available HER2/neu assay using the 
ADVIA Centaur system (Siemens Healthcare Diagnostics, 
Deerfield, IL, USA). This automated immunoassay uses two 
monoclonal antibodies (TA-1 and NB-3) for the detection 
of HER2 protein. The chemiluminescence signal is directly 
proportional to the quantity of HER2 protein in the sample. 
Each assay was controlled by two commercial controls (Siemens 
Healthcare Diagnostics) and one in-house serum pool. The 
assay shows an acceptable inter-assay coefficient of variation 
(CV) between 4.4 and 5.6%.
Tissue HER2 status was determined on paraffin-
embedded tumor tissue using the IHC and FISH methods. The 
tumors were considered HER2-positive if defined IHC3+ or 
IHC2+ combined with FISH ≥2. IHC analysis was assessed 
by HercepTest™ (DakoCytomation, Glostrup, Denmark). 
Figure 1. Diagram outlining the exclusion of patients. pts, patients.
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IHC0 and IHC1+ were considered HER2-negative, whereas 
IHC3+ was defined as HER2-positive. IHC2+ was consid-
ered borderline and in these cases HER2 expression was 
further determined using the HER2 FISH pharmDx™ kit 
(DakoCytomation). The threshold for overexpression was a 
ratio equal to or exceeding 2.0 between the HER2 gene copy 
number and the chromosome 17 centromere.
ER staining was carried out using an anti-human ER 
monoclonal antibody (clone 1D5; DakoCytomation) and visu-
alized by the SuperSensitive polymer-HRP IHC kit (Biogenex 
Laboratories Inc., San Ramon, CA, USA). Tumors with a 
nuclei staining ≥10% were considered ER-positive according 
to the contemporary DBCG guidelines.
Statistical methods. We enrolled 400 patients to detect a 25% 
absolute reduction in the risk of IDFS events from 45 to 20% 
with 80% power and a two-sided significance level of 5%. The 
statistical analyses were carried out using Stata version 11 soft-
ware (StataCorp LP, TX, USA). Kaplan-Meier curves and the 
log-rank test were used to compare all time-to-event end points. 
Multivariate IDFS and OS analyses were performed using the 
Cox proportional hazards regression model. Fisher's exact test 
and McNemar's test were used to compare categorical data. 
ROC curves were used to investigate the cut-off for the quan-
titative Centaur assay. For all tests, two-sided P-values <0.05 
were considered statistically significant.
Results
Patient characteristics. Final analysis included 379 patients. 
At the clinical cut-off date (September 19, 2011) the median 
follow-up was 3.9 years for IDFS and 4.2 years for OS. We 
compared the clinical outcome in four groups of patients 
defined by HER2 status (determined by IHC/FISH and 
Centaur) and adjuvant HER2-targeted therapy. The four 
groups were defined as follows: Group 0, patients defined as 
tissue HER2-negative by IHC/FISH and ADVIA Centaur and 
therefore not offered HER2-targeted therapy. Group 1, patients 
defined as tissue HER-positive by IHC/FISH and therefore 
offered HER2-targeted therapy. Group 2, patients defined as 
tissue HER2-positive by IHC/FISH, but not offered HER2-
targeted therapy, as they were older than 60 years and therefore 
only received endocrine treatment when adjuvant treatment 
was required according to the recommendations by the contem-
porary DBCG guidelines. Group 3, patients defined as tissue 
HER2-positive by ADVIA Centaur, but not by IHC/FISH and 
therefore not offered HER2-targeted therapy.
Table I shows patient demographics and clinical char-
acteristics in the four groups. Clinical prognostic factors 
were significantly better in group 3 compared to group 1 as 
regards tumor grade, axillary nodal status and ER status 
(P=0.001, 0.026 and <0.001, respectively; Fisher's exact test). 
Furthermore, Table I shows that the majority of patients in 
groups 1 and 2 were also defined as tissue HER2-positive by 
ADVIA Centaur. Likewise, differences in adjuvant treatment 
were observed as indicated in Table II. Significantly fewer 
patients in group 3 compared to group 1 received adjuvant 
chemotherapy (P<0.001; Fisher's exact test).
HER2 status determined by IHC/FISH and ADVIA Centaur. 
Paraffin-embedded and fresh-frozen tumor tissue samples 
were available from all 379 patients for IHC/FISH and ADVIA 
Centaur analyses. The cut-off value of 72 ng/mg protein for 
ADVIA Centaur HER2 positivity was determined on avail-
able auto logous reference tissue from 371 out of 403 patients 
applying a 97.5% confidence interval (CI). As shown in our 
previous study [Olsen et al (17)], we found the median value of 
HER2 to be significantly higher in the tumor tissue (median, 
42.3 ng/mg; range, 0-6158.2 ng/mg) than in autologous refer-
ence tissue (2.6 ng/mg; range, 0-862.8 ng/mg; P<0.0001; 
Wilcoxon signed rank test on 367 patients with both tumor and 
autologous reference tissue).
Using the cut-off value of 72 ng/mg, the quantitative 
ADVIA Centaur defined 100 out of the 379 patients (26.4%) as 
tissue HER2-positive, whereas only 63 patients (16.6%) were 
defined HER2-positive by the use of IHC/FISH (P<0.0001; 
Figure 2. Distribution of ADVIA Centaur values according to the four different groups of patients defined by tissue HER2 status (IHC3+ or IHC2+ with 
FISH ≥2 or Centaur >72 ng/mg cut-off value), +/- adjuvant HER2-targeted therapy. neg, negative; pos, positive; adj, adjuvant HER2 targeted therapy.
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McNemar's test). The ADVIA centaur misclassified only 5 out 
of the 63 patients defined as tissue HER2-positive by IHC/
FISH as shown in Table I. Fig. 2 shows the distribution of 
ADVIA Centaur values according to the four different groups; 
it should be noted that only five values in groups 1 and 2 are 
below the cut-off value of 72 ng/mg.
Table I. Demographics and clinical characteristics in the four groups of patients defined by HER2 status (determined by IHC/
FISH and Centaur), +/- adjuvant HER2-targeted therapy.
 Group 0 Group 1 Group 2 Group 3
 HER2-neg HER2-pos HER2-pos HER2-pos
 - adj IHC/FISH + adj IHC/FISH - adj Centaur - adj
 (n=274)  (n=42) (n=21) (n=42) ----------------------------- ------------------------------  ------------------------------ -----------------------------
Characteristic No. % No. % No. % No. % P-valuea
Age
  <40 years 6 2.2 4  9.5
  40-59 years 111 40.5 25  59.5 4 19.0 23  54.8
  ≥60 years 157  57.3 13  31.0 17 81.0 19  45.2 0.091
Type of surgery
  Breast-conserving 192  70.1 30 71.4 16  76.2 34  81.0
  Mastectomy 82 29.9 12 28.6 5  23.8 8 19.0 0.443
Tumor type
  Ductal  236  86.1 38 90.5 19  90.5 37  88.1
  Lobular 21 7.7 2 4.8   2  4.8
  Others 17 6.2 2 4.8 2  9.5 3  7.1 1.000
Tumor grade
  Grade 1 68 24.8 1 2.4 1 4.8 12 28.6
  Grade 2 132 48.2 20  47.6 7 33.3 21 50.0
  Grade 3 56 20.4 17  40.5 11 52.4 6 14.3
  Unknown 18 6.6 4  9.5 2 9.5 3 7.1 0.001
Tumor size
  T1 ≤20 mm 130 47.4 17 40.5 9  42.9 24 57.1
  T2 >0 ≤50 mm 138 50.4 24 57.1 12  57.1 18 42.9
  T3 >50 mm 6  2.2 1 2.4     0.190
Nodal status
  N0, 0 nodes 127 46.4 18 42.9 11 52.4 26 61.9
  N1, 1-3 nodes 106 38.7 12 28.6 8  38.1 14 33.3
  N2, 4-9 nodes 28 10.2 8 19.0 2  9.5 1 2.4
  N3, ≥10 nodes  13 4.7 4  9.5   1 2.4 0.026
ER status
  Negative 38 13.9 18  42.9 6 28.6 3  7.1
  Positive 236 86.1 24  57.1 15 71.4 39 92.9 <0.001
HER2 IHC/FISH
  Negative 274      42
  Positive   42  21    NA
HER2 Centaur
  Negative <72 ng/mg 274  4  1
  Positive ≥72 ng/mg   38  20  42  NA
aClinical prognostic factors in group 1 and group 3 were compared by Fisher's exact test. neg, negative; pos, positive; adj, adjuvant HER2 
targeted therapy.
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Invasive disease-free survival. Follow-up was available for 
all 379 patients in the final analysis. At a median follow-up of 
3.9 years (0.3-6.9 years), there were 74 events in the four groups, 
45 distant recurrence, 11 regional invasive breast cancer recur-
rence or ipsilateral/contralateral invasive breast cancer, 10 died 
from non-breast cancer/unknown cause, and eight had second 
primary non-breast invasive cancer. No significant difference 
in IDFS was found among the four groups (P=0.159; log-rank). 
Surprisingly, we found a significantly greater number of events 
in group 2 compared to group 3 (P=0.025; log-rank), with 
eight events in 21 patients in the IHC/FISH-positive group not 
receiving adjuvant HER2-targeted treatment (group 2) and 
only five events in 42 patients in the Centaur-positive group not 
receiving adjuvant HER2-targeted treatment (group 3) (Fig. 3).
Overall survival. At a median follow-up of 4.2 years 
(0.3-6.9 years), the four groups had a total of 39 events (29 died 
from breast cancer and 10 died from non-breast cancer/unknown 
cause). As for IDFS, no significant difference in survival was 
observed among the four groups (P=0.150; log-rank); however, 
a significantly higher number of deaths was observed in group 2 
compared to group 3 (P=0.020; log-rank) (Fig. 4).
Univariate and multivariate analysis. Table III shows the 
results of the univariate analysis with dichotomized variables, 
Table II. Adjuvant therapy in the four groups of patients defined by HER2 status (determined by IHC/FISH and Centaur), 
+/- adjuvant HER2-targeted therapy.
 Group 0  Group 1  Group 2  Group 3 
 HER2-neg HER2-pos HER2-pos HER2-pos
 - adj IHC/FISH + adj IHC/FISH - adj Centaur - adj
 (n=274)  (n=42) (n=21) (n=42)
Adjuvant --------------------------------- -------------------------------  ------------------------------- -------------------------------
therapy No. % No. % No. % No. % P-valuea
Chemotherapy
  No 171 62.4 1 2.4 19 90.5 23 54.8
  CEF 42 15.3 13 31.0   4 9.5
  CMF 1 0.4 1 2.4 2 9.5
  EC + D 47 17.2 27 64.3   14 33.3
  DC 13 4.7     1 2.4 <0.001
HER2-targeted
  No 274 100.0    21 100.0 42 100.0
  Herceptin    28 66.7
  Neratinibb    4 9.5
  Lapatinibb    10 23.8     <0.001
Endocrine
  No 70 25.5 17 40.5 7 33.3 11 26.2
  Tam 45 16.4 7 16.7 1 4.8 6 14.3
  Tam + AIc 107 39.1 7 16.7 7 33.3 16 38.1
  AI  52 19.0 11 26.2 6 28.6 9 21.4 0.165
Radiotherapy
  No 49 17.9 4 9.5 6 28.6 6 14.3
  Yes 225 82.1 38 90.5 15 71.4 36 85.7 0.738
aDifferences in the adjuvant therapy in groups 1 and 3 were compared by Fisher's exact test. bIn combination with Herceptin. cTamoxifen 
followed by an aromatase inhibitor. neg, negative; pos, positive; adj, adjuvant HER2 targeted therapy.
Table III. Univariate analysis of prognostic factors for IDFS 




Age, <60 vs. ≥60 years 0.207 0.055
Tumor grade, grade <3 vs. grade 3 <0.001 <0.001
Tumor size, ≤ 20 vs. >20 mm 0.058 0.009
Lymph nodes, neg/pos 0.206 0.012
ER status, neg/pos 0.111 0.049
HER2 IHC/FISH, neg/pos 0.228 0.522
HER2 Centaur, <72 vs. ≥72 ng/mg 0.651 0.670
Univariate analysis was performed using the log-rank test. Median 
follow-up was 3.9 years for IDFS and 4.2 years for OS. neg, negative; 
pos, positive.
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identifying tumor grade (grade of <3 vs. grade 3), tumor size 
(≤20 vs. >20 mm), axillary node status (negative vs. positive) and 
estrogen receptor status (negative vs. positive) as statistically 
significant for OS, whereas only tumor grade was statistically 
significant for IDFS. HER2 status (negative vs. positive) was 
not significant in the univariate analysis, neither when deter-
mined by IHC/FISH nor by Centaur (<72 vs. ≥72 ng/mg).
The variables in the multivariate analysis included group 
(also representing HER2 status), age, tumor grade, tumor size, 
axillary node status and ER-status as outlined in Table IV. In 
the multivariate analysis for IDFS, the only independent prog-
nostic marker was tumor grade (P=0.011). In the multivariate 
analysis for OS age (P=0.048), tumor grade (P=0.010) and 
axillary node status (P=0.025) were independent prognostic 
markers. Groups determined by HER2 status were not an 
independent prognostic factor in the above analysis.
ROC curve analysis. We also investigated the ability of the 
quantitative Centaur assay to discriminate between patients with 
or without recurrence. The ROC curve analyses resulted in an 
almost straight line with an area under the ROC curve of 0.49, 
which implies that the Centaur assay was not able to discriminate 
between patients at all. In accordance with this finding, there 
were no statistically significant differences observed between 
the mean Centaur value in patients with or without recurrence in 
any of the four groups of patients in this study (data not shown).
Figure 3. Kaplan-Meier plot showing invasive disease-free survival in the four groups of patients based on HER2 status (determined by IHC/FISH and Centaur), 
+/- adjuvant HER2-targeted therapy.
Figure 4. Kaplan-Meier plot showing overall survival in the four groups of patients based on HER2 status (determined by IHC/FISH and Centaur), +/- adjuvant 
HER2-targeted therapy.
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Discussion
In the current study, we reject the hypothesis that the clinical 
outcome is worse in a group of patients defined as tissue 
HER2-positive by Centaur only and not treated with adjuvant 
HER2-targeted therapy compared to patients defined as HER2-
positive by IHC/FISH and treated with adjuvant HER2-targeted 
therapy. In fact, the best outcome was observed in the group of 
patients defined as HER2-positive by Centaur only. In contrast 
to this finding, Konecny et al (18) demonstrated an association 
between HER2 overexpression by ELISA and shorter disease-
free survival (DFS) in a cohort of 587 patients with primary 
breast cancer prior to the era of HER2-targeted therapy. 
Currently, adjuvant HER2-targeted therapy is the standard of 
care for HER2-positive breast cancer patients. Scrutiny of the 
clinically relevant question as to whether we could increase the 
number of patients eligible for adjuvant HER2-targeted therapy 
could only be done in a design such as the present one followed 
by a prospective intervention study.
A number of studies have indicated the existence of an 
additional group that may benefit from adjuvant HER2-targeted 
therapy. First, as shown in a previous study [HERceptin 
Adjuvant (HERA) trial], among patients defined as HER2-
positive by IHC and FISH (IHC2+ and FISH+), a significant 
improvement in clinical outcome was observed in patients 
treated with adjuvant chemotherapy plus trastuzumab for one 
year (19). Second, Gilcrease et al (20) demonstrated that even 
a low-level HER2 expression (IHC1+) can be associated with a 
worse outcome in node-positive patients. Finally, the study by 
Viale raised an ongoing discussion regarding the misclassifica-
tion of some patients by FISH using HER2/CEP17 ratio instead 
of relating the HER2 copy number to the cell count (21).
The cut-off value of 72 ng/mg used in this study is consistent 
with the cut-off value of 400 fmol/mg (~74 ng/mg) found by 
Konecny et al (18), who optimized the cut-off value to provide 
the maximum separation of patients according to DFS. On the 
other hand, Müller et al (22) applied ROC statistics to optimize 
their cut-off value (42 ng/mg) according to the FISH results. If 
we had used this lower cut-off value, we would have defined 
51% of the patients as HER2-positive (193 out of 379 patients). 
In contrast to these two studies, we aimed to find a novel and 
more sensitive assay and therefore chose to investigate Centaur 
HER2 as a biological variable and defined the cut-off value 
in our study according to the autologous reference tissue by 
applying a 97.5% CI.
Another unexpected, although interesting finding of this 
study was that the HER2-positive patients in group 2 (age ≥ 60) 
had a worse outcome than expected, possibly due to the lack 
of adjuvant HER2-targeted therapy. This emphasizes the need 
for a change in clinical practice where many elderly patients 
Table IV. Multivariate analysis of prognostic factors for IDFS and OS in 379 patients.
 IDFS OS ------------------------------------------------------------------------ -----------------------------------------------------------------------
Factor HR (95% CI) P-value HR (95% CI) P-value
Group
  0, HER2-neg - adj 1.00  1.00
  1, IHC/FISH pos + adj. 0.94 (0.43-2.05) 0.879 0.72 (0.21-2.49) 0.602
  2, IHC/FISH pos - adj. 1.49 (0.69-3.21) 0.306 1.29 (0.49-3.39) 0.602
  3, Centaur pos - adj. 0.65 (0.26-1.62) 0.352 0.27 (0.04-2.01) 0.202
Age
  <60 years 1.00  1.00
  ≥60 years 1.35 (0.83-2.22) 0.231 2.04 (1.00-4.15) 0.048
Tumor grade
  Grade 1, 2, unknown 1.00  1.00
  Grade 3 1.94 (1.16-3.24) 0.011 2.48 (1.24-4.97) 0.010
Tumor size
  ≤20 mm 1.00  1.00
  >20 mm 1.32 (0.80-2.17) 0.624 1.80 (0.85-3.83) 0.124
Axillary node status
  Negative 1.00  1.00
  Positive  1.33 (0.82-2.17) 0.245 2.32 (1.11-4.83) 0.025
ER status
  Negative 1.00  1.00
  Positive 0.78 (0.43-1.41) 0.411 0.60 (0.28-1.29) 0.195
Statistical analysis was performed by the Cox regression analysis. Median follow-up was 3.9 years for IDFS and 4.2 years for OS. neg, nega-
tive; pos, positive; adj, adjuvant HER2 targeted therapy.
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are not selected for adjuvant chemotherapy and HER2-targeted 
therapy based on age only. Furthermore, Palmieri et al (23) 
reported a worse outcome in patients who were not offered 
HER2-targeted therapy due to a clinical judgment that the 
breast cancer was low-risk. Likewise, Tovey et al (24) empha-
sized the need for HER2-targeted therapy even in low-grade, 
node-negative tumors. Sawaki et al (25) showed that elderly 
patients tolerated trastuzumab well, which highlights the need 
for a new view of elderly patients and adjuvant HER2-targeted 
therapy.
In conclusion, the main finding of the present study is 
that quantitative the detection of HER2 concentration using 
Centaur does not define a new group of patients eligible for 
HER2-targeted therapy. Therefore, tissue HER2 status defined 
by IHC/FISH analysis remains the gold standard. HER2 
amplification is presumably the decisive factor, which, in addi-
tion to an overexpression of the HER2 protein, leads to the 
aggressive nature of HER2-positive tumors. Further studies 
are therefore warranted in order to identify novel methods of 
detecting this amplification.
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